Exelixis
EXEL
#1698
Rank
A$15.21 B
Marketcap
$53.29
Share price
0.23%
Change (1 day)
67.13%
Change (1 year)
Exelixis, Inc. is an American genomics-based drug discovery company and the producer of Cometriq, a treatment for medullary thyroid cancer.

Exelixis (EXEL) - Total debt

Total debt on the balance sheet as of September 2024 : A$0.29 Billion

According to Exelixis's latest financial reports the company's total debt is A$0.29 Billion. A companyโ€™s total debt is the sum of all current and non-current debts.

Exelixis - Total debt on balance sheet (from 2000 to 2024)

Total debt by year

Year Total debt Change
2023-12-31A$0.27 B-0.24%
2022-12-31A$0.27 B295.15%
2021-12-31A$70.72 M10.79%
2020-12-31A$63.83 M-6.91%
2019-12-31A$68.57 M223.87%
2018-12-31A$21.17 M10.66%
2017-12-31A$19.13 M-92.71%
2016-12-31A$0.26 B-54.27%
2015-12-31A$0.57 B31.53%
2014-12-31A$0.43 B12.04%
2013-12-31A$0.38 B20.5%
2012-12-31A$0.32 B82.5%
2011-12-31A$0.17 B-13.74%
2010-12-31A$0.20 B131.55%
2009-12-31A$88.62 M-46.86%
2008-12-31A$0.16 B20.01%
2007-12-31A$0.13 B-9.94%
2006-12-31A$0.15 B-24.14%
2005-12-31A$0.20 B6.83%
2004-12-31A$0.19 B27.42%
2003-12-31A$0.14 B13.88%
2002-12-31A$0.13 B36.84%
2001-12-31A$95.9 M258.66%
2000-12-31A$26.73 M32.11%
1999-12-31A$20.23 M

Total debt for similar companies or competitors

Company Total debt/th> differencediff. Country
A$32.97 B 10,953.10%๐Ÿ‡ฌ๐Ÿ‡ง UK
A$39.06 B 12,994.04%๐Ÿ‡ซ๐Ÿ‡ท France
A$58.50 B 19,510.17%๐Ÿ‡บ๐Ÿ‡ธ USA
A$78.86 B 26,334.21%๐Ÿ‡บ๐Ÿ‡ธ USA
A$92.67 B 30,961.74%๐Ÿ‡บ๐Ÿ‡ธ USA
A$54.85 B 18,286.18%๐Ÿ‡บ๐Ÿ‡ธ USA
A$102.21 B 34,160.07%๐Ÿ‡บ๐Ÿ‡ธ USA
A$5.45 M-98.17%๐Ÿ‡บ๐Ÿ‡ธ USA
A$59.35 M-80.11%๐Ÿ‡บ๐Ÿ‡ธ USA